Cellectar Biosciences' Iopofosine I 131 Efficacy Data Accepted for ASCO Presentation
Summary
Cellectar Biosciences announced that efficacy results from a subset of its CLOVER WaM clinical trial for iopofosine I 131 in relapsed or refractory Waldenström Macroglobulinemia (r/r WM) patients have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in May-June 2026. This news follows a recent 10-K filing that raised substantial doubt about the company's ability to continue as a going concern, making any positive clinical development crucial. The company highlighted "highly encouraging" safety and efficacy results, suggesting iopofosine I 131 could address a significant unmet need in a patient population with no approved therapies. This creates a strong near-term catalyst for the stock as investors will anticipate the full data presentation. Investors should monitor the actual presentation of the CLOVER WaM data at ASCO (May 29 - June 2, 2026) for the complete efficacy and safety profile.
At the time of this announcement, CLRB was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $2.43 to $20.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.